Policy

CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.

Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.

Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.

The Community Oncology Alliance is the only national organization focused exclusively on community oncology; it advocates for independent practices where most Americans with cancer receive treatment.

The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.

The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.

Chester Good, MD, MPH, shares data and strategies used by UPMC to evaluate value-based contracting in specialty pharmacy.

As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.

NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.

Jesse Dresser explains how federal PBM reform, a new CMS RFI, and FTC settlements could reshape specialty pharmacy contracts and pay from 2027.

Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.

A bioethicist explains why Kalshi's new FDA approval and clinical trial betting markets raise concerns about bias, herd behavior, and insider trading.

All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.

Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.

ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.

Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.

Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.

PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.

Reference countries have limited room to simply raise their own drug budgets to absorb the pressure, the lead study author explains.

Trial, transplant equity gaps in AML; Texas Medicaid funding dispute; pediatric GLP-1 access gaps; earlier biologic use; eye care restores vision.

Policy changes could have the greatest impact on transplant equity, explains hematologic oncologist Karilyn Larkin, MD.

NCCN survey finds universal, persistent generic drug shortages; coping tactics stretch teams as looming tariffs threaten more supply disruptions.

CMS is withholding $9.8 billion in Texas Medicaid hospital funding tied to CHIRP, costing hospitals $27 million a day in a tax dispute.